Cargando…

Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection

Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown that materna...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarot, Emiliano, Naimo, Eleonora, Corrado, Alessia, Giannetti, Patrizia, Ros, Immaculada Margarit Y., Bensi, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560876/
https://www.ncbi.nlm.nih.gov/pubmed/34725414
http://dx.doi.org/10.1038/s41598-021-00941-z
_version_ 1784593012917010432
author Chiarot, Emiliano
Naimo, Eleonora
Corrado, Alessia
Giannetti, Patrizia
Ros, Immaculada Margarit Y.
Bensi, Giuliano
author_facet Chiarot, Emiliano
Naimo, Eleonora
Corrado, Alessia
Giannetti, Patrizia
Ros, Immaculada Margarit Y.
Bensi, Giuliano
author_sort Chiarot, Emiliano
collection PubMed
description Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown that maternal vaccination with polysaccharide-based vaccines protects mothers and offspring from GBS mucosal colonization and consecutive infection. In these models, bacteria were inoculated in mouse either intravaginally in the last trimester of pregnancy or systemically in pups. Here, we investigated whether maternal vaccination with glycoconjugate vaccines may also prevent GBS-mediated colonization and disease in neonates using an infection route that more closely mimics inhalation or ingestion of bacteria during human delivery. To address this point, mice aged less than two days were intranasally challenged with epidemiologically relevant GBS strains. Bacteria were found to colonize nose and intestine, reaching in some cases lungs and blood during the first days of life. Bacteria were also found in vagina of a fraction of colonized female mice within the first month of life. GBS-specific IgG induced by maternal vaccination with a glycoconjugate vaccine formulation were found in blood and mucosal tissues of newborns. Finally, when intranasally challenged with GBS serotype III strains, pups delivered by vaccinated mothers were partially protected against mucosal colonization and deeper infection.
format Online
Article
Text
id pubmed-8560876
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85608762021-11-03 Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection Chiarot, Emiliano Naimo, Eleonora Corrado, Alessia Giannetti, Patrizia Ros, Immaculada Margarit Y. Bensi, Giuliano Sci Rep Article Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown that maternal vaccination with polysaccharide-based vaccines protects mothers and offspring from GBS mucosal colonization and consecutive infection. In these models, bacteria were inoculated in mouse either intravaginally in the last trimester of pregnancy or systemically in pups. Here, we investigated whether maternal vaccination with glycoconjugate vaccines may also prevent GBS-mediated colonization and disease in neonates using an infection route that more closely mimics inhalation or ingestion of bacteria during human delivery. To address this point, mice aged less than two days were intranasally challenged with epidemiologically relevant GBS strains. Bacteria were found to colonize nose and intestine, reaching in some cases lungs and blood during the first days of life. Bacteria were also found in vagina of a fraction of colonized female mice within the first month of life. GBS-specific IgG induced by maternal vaccination with a glycoconjugate vaccine formulation were found in blood and mucosal tissues of newborns. Finally, when intranasally challenged with GBS serotype III strains, pups delivered by vaccinated mothers were partially protected against mucosal colonization and deeper infection. Nature Publishing Group UK 2021-11-01 /pmc/articles/PMC8560876/ /pubmed/34725414 http://dx.doi.org/10.1038/s41598-021-00941-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chiarot, Emiliano
Naimo, Eleonora
Corrado, Alessia
Giannetti, Patrizia
Ros, Immaculada Margarit Y.
Bensi, Giuliano
Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_full Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_fullStr Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_full_unstemmed Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_short Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_sort maternal vaccination with a type-iii glycoconjugate protects mouse neonates against group b streptococcus intranasal infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560876/
https://www.ncbi.nlm.nih.gov/pubmed/34725414
http://dx.doi.org/10.1038/s41598-021-00941-z
work_keys_str_mv AT chiarotemiliano maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
AT naimoeleonora maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
AT corradoalessia maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
AT giannettipatrizia maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
AT rosimmaculadamargarity maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
AT bensigiuliano maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection